33.5 C
New York
Friday, June 12, 2026

Tag: SAFE

newssourceFORcompanyinformationcontent1marketreleases

Clear Robotics Lands $1.75M to Build the World’s Largest Fleet of Zero-Emission Autonomous Ships

HONG KONG, June 8, 2026 /PRNewswire/ -- Today, Clear Robotics, a Hong Kong founded maritime technology company, announced that it closed a $1.75 million...

Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions

SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 5, 2026, Calterah, a global leader in mmWave radar chips, unveiled its latest high-performance radar SoCs for...

Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions

SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 5, 2026, Calterah, a global leader in mmWave radar chips, unveiled its latest high-performance radar SoCs for...

HTX Launches “Appreciation Program” with Over $10 Million to Reward User Trust

APIA, Samoa, June 8, 2026 /PRNewswire/ -- Amid the rapid iteration of the crypto industry and the constant shifts in market conditions, the relationship...

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

MAS Pathfinder Programme listing reflects Finnate's governance-focused design and real-world deployment maturity across regulated financial servicesMELBOURNE, Australia, June 8, 2026 /PRNewswire/ -- Centelon announced that...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

The Canadian Food Inspection Agency implements disease control measures to prevent spread of New World Screwworm

OTTAWA, ON, June 5, 2026 /CNW/ - Following a confirmed finding of New World screwworm in a calf in Texas, the Canadian Food Inspection...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSAFE

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers